Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk CEO defending GLP-1 pricing and the push to lower prices.

Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's ...

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

In an interview with Peers & Perspectives in Oncology, Sherry Shen, MD, discusses the GLP-1 agonists analyzed for weight ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

Harvard Medical School professor Joel F. Habener won the 2024 Lasker-DeBakey Clinical Medical Research Award for his work on ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

Employers that cover GLP-1s are partnering with vendors to design benefits and manage lifestyle programs, but the "jury is ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

USA: A recent comparative study has uncovered promising evidence that GLP-1 receptor agonists may offer significant ocular ...

GLP-1 agonists, widely used for obesity and diabetes management, have been associated with a reduced risk of most ...

Natural supplements have “very mild effects” on weight loss based on what Dr. Ali has seen. There is some data to suggest ...